NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Anju SinghAnneleen DaemenDorothee NicklesSang-Min JeonOded ForemanKuladeep SudiniFlorian GnadStephane LajoieNaina GourWayne MitznerSamit ChatterjeeEun-Ji ChoiBuvana RavishankarAmy RappaportNamrata PatilMark McClelandLeisa JohnsonGeorge K Acquaah-MensahEdward GabrielsonShyam BiswalGeorgia HatzivassiliouPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our in vivo modeling establishes NRF2 activation as a critical oncogenic driver, cooperating with STK11 loss and KRAS activation to promote aggressive lung adenocarcinoma. In patients, oncogenic events alter the tumor immune contexture, possibly having an impact on treatment responses. Importantly, patients with NRF2-activated nonsquamous or squamous tumors have poor prognosis and show limited response to anti-PD-L1 treatment.